Zydus Lifesciences gains on getting USFDA’s final approval for Niacin Extended-Release Tablets

30 Apr 2025 Evaluate

Zydus Lifesciences is currently trading at Rs. 894.40, up by 6.45 points or 0.73% from its previous closing of Rs. 887.95 on the BSE.

The scrip opened at Rs. 887.95 and has touched a high and low of Rs. 901.80 and Rs. 887.80 respectively. So far 10533 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 901.80 and Rs. 857.90 respectively. The current market cap of the company is Rs. 89937.19 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg (Niaspan Extended-Release Tablets, 500 mg, 750 mg, and 1,000 mg).

Niacin is indicated to reduce elevated total cholesterol (TC), LDL cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase HDL cholesterol (HDL-C) in patients with primary hyperlipidaemia and mixed dyslipidaemia. It is also indicated to reduce the risk of recurrent myocardial infarction in patients with a history of myocardial infarction and hyperlipidaemia and to reduce TG in adult patients with severe hypertriglyceridemia. Niacin-Extended-Release tablets will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad.

Niacin-Extended-Release tablets had annual sales of $5.5 million in the United States (IQVIA MAT February 2025). The group now has 425 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×